newsfilter
← Latest News
GlobeNewswire·

AEON Biopharma Sets Annual Shareholder Meeting

  • AEON Biopharma Annual Shareholder Meeting scheduled for 10:00 am PT on June 17, 2026, at company offices in Irvine, CA.
  • Meeting materials expected to be available to shareholders on or about April 29, 2026.
  • Audited financial statements for fiscal year 2025 included a going concern qualification due to liquidity position.
  • Company expects cash & cash equivalents to fund operations into the third quarter of 2026.
  • ABP-450 is a biosimilar to BOTOX developed for full-label U.S. therapeutic neurotoxin market entry.
  • ABP-450 is manufactured by Daewoong Pharmaceutical in facilities authorized by U.S. FDA, Health Canada, & EMA.
  • ABP-450 is already approved as a biosimilar in India, Mexico, & the Philippines.
  • AEON holds exclusive development & distribution rights for ABP-450 therapeutic indications in U.S., Canada, EU, UK, & other territories.
  • The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually.
  • Forward-looking statements include risks regarding stock exchange listing standards, financing, & financial performance.